The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | The value of BTK inhibitors in CLL & the future of acalabrutinib in this disease
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, gives an overview of how Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), highlighting both covalent and non-covalent BTK inhibitors. Following this, Dr Niemann shares some insights into how the use of acalabrutinib is likely to advance in CLL, commenting on the importance of combination approaches and time limited treatment. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding and/or consultancy fees from Abbvie, Janssen, AstraZeneca, Beigene, Octapharma, Genmab, Takeda, CSL Behring, Eli Lilly
